Luxempart (LXMPR) H2 2024 earnings summary
Event summary combining transcript, slides, and related documents.
H2 2024 earnings summary
10 Feb, 2026Executive summary
Net Asset Value (NAV) at year-end 2024 was €2,311m, down 0.6% year-over-year, with a global performance of +1.3% for the year, outperforming the 4-year benchmark IRR of 10% versus 5.2% for the MSCI Europe Mid Cap index.
Investment Funds delivered an 8.5% return, while Direct Investments were flat at -0.1%, impacted by sector-specific downturns in a few holdings.
€152m was deployed in new investments, with €87m in Direct Investments and €65m in Investment Funds; €228m was cashed in from exits and proceeds.
The company maintained a strong liquidity position with €184m in cash and €200m in undrawn credit facilities.
A dividend of €2.33 per share is proposed, a 7.4% increase, reflecting a 3.3% yield.
Financial highlights
NAV: €2,311m at 31/12/2024, down 0.6% from prior year.
Global performance: +1.3% in 2024; 4-year IRR of 10%.
Direct Investments: -0.1% performance; NAV decreased by 5.6% to €1,531m.
Investment Funds: +8.5% performance; NAV increased to €588m.
Dividend: €2.33 per share proposed (+7.4% YoY); 3.3% yield.
Stock performance: +10.1% (including dividend) in 2024.
Outlook and guidance
No formal guidance for 2025 due to high unpredictability.
Positive signs in cyclical holdings and continued strong activity in most portfolio companies.
Ongoing low M&A activity may impact fund IRRs and slow portfolio construction.
US diversification strategy expected to buffer potential shocks.
Latest events from Luxempart
- NAV up 6.4% to €2.3bn, net profit €183.5m, and dividend up 9.6% amid strong investment activity.LXMPR
H2 202310 Feb 2026 - NAV up 2.3% to €2.23bn, €89m profit, and strong direct investment activity in H1 2023.LXMPR
H1 202310 Feb 2026 - Stable NAV, strong liquidity, and selective investments amid challenging market conditions.LXMPR
H1 202410 Feb 2026 - NAV up 0.7% to €2,327m, profit at €62.9m, and strong liquidity support a stable outlook.LXMPR
H1 202510 Feb 2026